Bringing new medicines
to everyone
CLINIAL drives the visualization and utilization of healthcare data through engineering.
Delivering advanced healthcare
to everyone
Of the new medicines developed worldwide each year, less than 30% become available in Japan*.
Unless clinical trials are run at hospitals and the latest drugs are approved for use, patients cannot receive the most advanced treatments. Japan has long struggled with this problem, known as “drug loss”—a systemic issue that drastically delays patient access to unapproved innovative drugs.
One root cause is that the systems for using electronic health record (EHR) and clinical trial data are not sufficiently mature in Japan, so essential information does not reach the people who need it.
As a result, patients cannot enroll in clinical trials matched to their condition, and medical institutions and pharmaceutical companies cannot make decisions based on real-world data.
CLINIAL exists to solve this structural problem.
By combining deep expertise in clinical trials and oncology with IT engineering, we accelerate the visualization of healthcare data and help deliver appropriate care to more people.
* Nikkei, November 14, 2023
Solutions
CliniCONNECT®
A system that integrates disparate hospital data into a single platform, enabling cross-departmental patient search and analysis of healthcare data.
Evidence-based clinical
decision support
We analyze the data collected and normalized through CliniCONNECT® to support evidence generation and the publication of research findings.
Hospital–industry
joint research
We drive feasibility studies and data analysis toward realizing joint research.
Clinical trial program
launch & scale support
We support recruitment from inside and outside the hospital for trial sites, and the digital transformation (DX) of clinical-trial operations.
News
CEO Takaaki Mizuno spoke at an internal training session of Daiichi Sankyo Co., Ltd.
Takaaki Mizuno, CEO of CLINIAL Inc. (Shibuya-ku, Tokyo), gave a lecture at an internal training sess……
Joint research results with the National Cancer Center Japan accepted for ECR 2026 (Vienna, Austria)
For ECR 2026 (European Congress of Radiology), to be held in Vienna, Austria, "Evaluating the Applic……
Completed a fundraising round
CLINIAL Inc. (Shibuya-ku, Tokyo; CEO: Takaaki Mizuno) has completed a seed round raising a total of ……
Member
MD, PhD. Project Assistant Professor at the Cancer Genome Medicine Center, Keio University School of Medicine, and Visiting Researcher in the Department of Medical Informatics at the National Cancer Center Hospital. He is a Board-Certified Medical Oncologist and Certified Instructor (JSMO), a Board-Certified Pulmonologist and Certified Instructor (JRS), and a Board-Certified Specialist of the Japanese Society of Internal Medicine. He has served as an advisor to pharmaceutical, medical device, and startup companies, and as a medical expert has participated in the design, regulatory affairs, and operation of industry-sponsored Phase I clinical trials. He has conducted investigator-initiated trials and basic research under multiple competitive research grants from AMED (Japan Agency for Medical Research and Development). As a researcher, he has received honors including the IASLC Asia 2018 - Best abstract Award and the 2022 Director's Award at the National Cancer Center Research Institute Young Investigators Seminar.
He began his career at NTT Communications Corporation, where he was responsible for infrastructure. From 2018, he served as Executive Officer at FOLIO Co., Ltd. and as CIO of SBI Security Solutions Co., Ltd., leading system development in the securities and financial sectors. From 2023, as Director and CTO of Henry Inc., he oversaw the development of cloud-based electronic medical record and medical insurance claim systems. He took part in the product working group for the revision work on the alpha version of the Digital Agency's standardized electronic medical record system in preparation for its full-scale rollout. He has held his current position since November 2025.
MD, PhD. At a global pharmaceutical company, he served as the executive in charge of R&D, medical affairs, regulatory affairs, safety, and quality assurance, as well as a member of the board of directors, building out the company's global governance framework. He led the approval and launch of several blockbuster products, managing the full continuum from R&D strategy through post-launch value maximization. He currently serves as President and CEO of Seriu Medical Consulting Co., Ltd., advising the boards and executive teams of pharmaceutical and biotech companies on R&D strategy, regulatory and safety affairs, quality, and organizational transformation. He is also a Senior Advisor to the Board of APCER Life Sciences and the Representative Director of the Drug Development Capability Promotion Organization (DDCP).